Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Yoshihiro Inamoto^#¹, Igor Petriček^#², Linda Burns³, Saurabh Chhabra⁴, Zack DeFilipp⁵, Peiman Hematti⁶, Alicia Rovó⁷, Raquel Schears⁸, Ami Shah⁹, Vaibhav Agrawal¹⁰, Aisha Al-Khinji¹¹, Ibrahim Ahmed¹², Asim Ali¹³, Mahmoud Aljurf¹⁴, Hassan Alkhateeb⁸, Amer Beitinjaneh¹⁵, Neel Bhatt⁴, Dave Buchbinder¹⁵, Michael Byrne¹⁶, Natalie Callander¹⁷, Kristina Fahnehjelm^{18

19}, Nosha Farhadfar²⁰, Robert Peter Gale²¹, Siddhartha Ganguly²², Gerhard C Hildebrandt²³, Erich Horn²⁰, Ann Jakubowski²⁴, Rammurti T Kamble²⁵, Jason Law²⁶, Catherine Lee²⁷, Sunita Nathan²⁸, Olaf Penack²⁹, Ravi Pingali³⁰, Pinki Prasad³¹, Drazen Pulanic^{32

33

34}, Seth Rotz³⁵, Aditya Shreenivas³⁶, Amir Steinberg³⁶, Khalid Tabbara³⁷, André Tichelli³⁸, Baldeep Wirk³⁹, Jean Yared⁴⁰, Grzegorz W Basak⁴¹, Minoo Battiwalla⁴², Rafael Duarte⁴³, Bipin N Savani⁴⁴, Mary E D Flowers⁴⁵, Bronwen E Shaw⁴⁶, Nuria Valdés-Sanz^#⁴⁷

Affiliations

¹ Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. yinamoto@ncc.go.jp.
² Department of Ophthalmology, University Clinical Hospital Zagreb, Zagreb, Croatia.
³ CIBMTR(Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, USA.
⁴ Medical College of Wisconsin, Milwaukee, WI, USA.
⁵ Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
⁶ Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, USA.
⁷ Universitatsspital Bern, Bern, Switzerland.
⁸ Mayo Clinic Rochester, Rochester, MN, USA.
⁹ Division of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, CA, USA.
¹⁰ Indiana University Simon Cancer Center, Indianapolis, IN, USA.
¹¹ University of California, San Francisco, CA, USA.
¹² Department of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, MO, USA.
¹³ St. Louis Medical Clinic, St. Louis, MO, USA.
¹⁴ Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
¹⁵ Division of Pediatrics Hematology, Children's Hospital of Orange County, Orange, CA, USA.
¹⁶ Vanderbilt University Medical Center, Nashville, TN, USA.
¹⁷ University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
¹⁸ Department of Clinical Neuroscience, Karolinska Institutet, St. Erik Eye Hospital, Stockholm, Sweden.
¹⁹ Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
²⁰ Shands Healthcare & University of Florida, Gainsville, FL, USA.
²¹ Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
²² Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS, USA.
²³ Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
²⁴ Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²⁵ Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
²⁶ Tufts Medical Center, Boston, MA, USA.
²⁷ Utah Blood and Marrow Transplant Program Huntsman Cancer Institute, University of Utaah, Salt Lake City, UT, USA.
²⁸ Rush University Medical Center, Chicago, IL, USA.
²⁹ Dept. of Internal Medicine, Div. Haematology & Oncology, Charité University Medicine, Campus Rudolf Virchow, Berlin, Germany.
³⁰ Houston Methodist Hospital, Houston, TX, USA.
³¹ Children's Hospital, New Orleans, LA, USA.
³² Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia.
³³ School of Medicine, University of Zagreb, Zagreb, Croatia.
³⁴ Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
³⁵ Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
³⁶ Division of Hematology and Oncology, Mount Sinai Hospital, New York, NY, USA.
³⁷ The School of Medicine, The Wilmer Ophthalmological Institute of The Johns Hopkins University, Baltimore, MD, USA.
³⁸ University Hospital Basel, Basel, Switzerland.
³⁹ Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA, USA.
⁴⁰ Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
⁴¹ Medical University of Warsaw, Warsaw, Poland.
⁴² Hematology Branch, Sarah Cannon BMT Program, Nashville, TN, USA.
⁴³ University Hospital Puerta de Hierro, Madrid, Spain.
⁴⁴ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴⁵ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁴⁶ CIBMTR (Center for International Blood and Marrow Transplant Program), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴⁷ Department of Ophthalmology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

^# Contributed equally.

PMID: 30531955
PMCID: PMC6497536
DOI: 10.1038/s41409-018-0339-6

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Yoshihiro Inamoto et al. Bone Marrow Transplant. 2019 May.

. 2019 May;54(5):648-661.

doi: 10.1038/s41409-018-0339-6. Epub 2019 Feb 27.

Authors

Affiliations

¹ Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. yinamoto@ncc.go.jp.
² Department of Ophthalmology, University Clinical Hospital Zagreb, Zagreb, Croatia.
³ CIBMTR(Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, USA.
⁴ Medical College of Wisconsin, Milwaukee, WI, USA.
⁵ Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
⁶ Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, USA.
⁷ Universitatsspital Bern, Bern, Switzerland.
⁸ Mayo Clinic Rochester, Rochester, MN, USA.
⁹ Division of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford School of Medicine, Palo Alto, CA, USA.
¹⁰ Indiana University Simon Cancer Center, Indianapolis, IN, USA.
¹¹ University of California, San Francisco, CA, USA.
¹² Department of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, MO, USA.
¹³ St. Louis Medical Clinic, St. Louis, MO, USA.
¹⁴ Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
¹⁵ Division of Pediatrics Hematology, Children's Hospital of Orange County, Orange, CA, USA.
¹⁶ Vanderbilt University Medical Center, Nashville, TN, USA.
¹⁷ University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
¹⁸ Department of Clinical Neuroscience, Karolinska Institutet, St. Erik Eye Hospital, Stockholm, Sweden.
¹⁹ Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
²⁰ Shands Healthcare & University of Florida, Gainsville, FL, USA.
²¹ Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
²² Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS, USA.
²³ Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
²⁴ Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²⁵ Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
²⁶ Tufts Medical Center, Boston, MA, USA.
²⁷ Utah Blood and Marrow Transplant Program Huntsman Cancer Institute, University of Utaah, Salt Lake City, UT, USA.
²⁸ Rush University Medical Center, Chicago, IL, USA.
²⁹ Dept. of Internal Medicine, Div. Haematology & Oncology, Charité University Medicine, Campus Rudolf Virchow, Berlin, Germany.
³⁰ Houston Methodist Hospital, Houston, TX, USA.
³¹ Children's Hospital, New Orleans, LA, USA.
³² Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia.
³³ School of Medicine, University of Zagreb, Zagreb, Croatia.
³⁴ Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia.
³⁵ Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
³⁶ Division of Hematology and Oncology, Mount Sinai Hospital, New York, NY, USA.
³⁷ The School of Medicine, The Wilmer Ophthalmological Institute of The Johns Hopkins University, Baltimore, MD, USA.
³⁸ University Hospital Basel, Basel, Switzerland.
³⁹ Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA, USA.
⁴⁰ Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
⁴¹ Medical University of Warsaw, Warsaw, Poland.
⁴² Hematology Branch, Sarah Cannon BMT Program, Nashville, TN, USA.
⁴³ University Hospital Puerta de Hierro, Madrid, Spain.
⁴⁴ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁴⁵ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁴⁶ CIBMTR (Center for International Blood and Marrow Transplant Program), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴⁷ Department of Ophthalmology, Hospital Universitario Puerta de Hierro, Madrid, Spain.

^# Contributed equally.

PMID: 30531955
PMCID: PMC6497536
DOI: 10.1038/s41409-018-0339-6

Erratum in

Correction: Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Al-Khinji A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Valdés-Sanz N. Inamoto Y, et al. Bone Marrow Transplant. 2019 May;54(5):782-783. doi: 10.1038/s41409-019-0472-x. Bone Marrow Transplant. 2019. PMID: 30809032

Abstract

Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest There are no conflicts of interest to discloset.

Figures

**Figure 2.**
Ocular infections after allogeneic hematopoietic cell transplantation

See this image and copyright information in PMC

References

1. Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373–3385. - PubMed
1. Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica 2017; 102: 614–625. - PMC - PubMed
1. Battiwalla M, Hashmi S, Majhail N, Pavletic S, Savani BN, Shelburne N. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. Biol Blood Marrow Transplant 2017; 23: 6–9. - PMC - PubMed
1. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12: 375–396. - PubMed
1. Dunn JP, Jabs DA, Wingard J, Enger C, Vogelsang G, Santos G. Bone marrow transplantation and cataract development. Arch Ophthalmol 1993; 111: 1367–1373. - PubMed

Publication types

Actions
Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Affiliations

Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical